
Opinion|Videos|January 13, 2025
Management of Alzheimer’s Disease with FDA-approved Disease-modifying Therapies
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves At-Home Starting Dose for Lecanemab, Marking First Subcutaneous Initiation Option for Alzheimer Disease Treatment
2
Anti-Tau Agent Diranersen Slows Cognitive Decline Across Multiple Endpoints in Phase 2 CELIA Trial, Biogen to Advance to Phase 3
3
Mitophagy Activator Urolithin A Enters Phase 2 Alzheimer Trial of APOE4 Carriers
4
Phase 2 APPLAUDS Trial to Test Mivelsiran in Down Syndrome-Associated Alzheimer Disease
5















